US panel to review Lilly/Daiichi's prasugrel in February
This article was originally published in Scrip
Executive Summary
The US FDA's cardiovascular and renal drugs advisory panel will meet on February 3rd to review Lilly/Daiichi Sankyo's Effient (prasugrel), further delaying US approval of the novel platelet inhibitor. The NDA was filed in December 2007 and designated for priority review. In June the FDA extended the review period by three months, later allowing the re-set September deadline to pass without action. The panel will be asked to weigh prasugrel's risks and benefits in light of results from the pivotal TRITON-TIMI 38 study, in which the drug provided a 19% reduction in major cardiovascular events compared with Sanofi-Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) in acute coronary syndrome patients undergoing percutaneous coronary intervention, albeit with a 32% increase in serious bleeding. In December the EU's CHMP granted a positive opinion recommending approval of prasugrel (as Efient).
You may also be interested in...
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.
Eye On ODAC: Former Members, FDA’s Pazdur Talk Pre-Meeting Mindsets, Impact Of Sponsor’s Experts
Oncologic Drugs Advisory Committee reps and the Oncology Center of Excellence director go behind the scenes to discuss FDA interactions with panelists, how opinions can change during a meeting, and why the voting question is important.